Navigating CML Treatment: A Patient-Centered Approach - Episode 6
Choosing First-Line TKI Therapy for CML: Expert Approaches to Risk Assessment & Treatment Selection
Panelists discuss how in selecting first-line therapy for patients with newly diagnosed chronic myeloid leukemia, clinicians must carefully weigh factors including the patient’s risk score, comorbidities, drug interaction potential, monitoring requirements, and cost considerations while recognizing that available tyrosine kinase inhibitor options (imatinib, nilotinib, dasatinib, and bosutinib) have similar efficacy but distinct safety and tolerability profiles.
Video content above is prompted by the following:
- How do you choose between these therapies when assessing a patient newly diagnosed with chronic myeloid leukemia?
- Please comment on any similarities or differences in your clinical practice when selecting between the first-line therapy options.
Related Content:
